Xsulin R Eris1pen Injection contains Human insulin (100 IU/mL) and is indicated for the management of diabetes mellitus requiring insulin therapy. This rapid-acting insulin formulation facilitates effective glycemic control by mimicking endogenous insulin secretion, thereby promoting cellular glucose uptake and utilization while inhibiting hepatic glucose production. Xsulin R Eris1pen is administered subcutaneously using a prefilled pen device, allowing for precise dosing and enhanced patient compliance. It is suitable for use in both type 1 and type 2 diabetes patients who do not achieve adequate glycemic control with oral hypoglycemic agents alone. The onset of action typically occurs within 30 minutes, with a peak effect at 2 to 4 hours and a duration of action lasting approximately 6 to 8 hours, making it ideal for mealtime glucose regulation. Dose adjustments should be individualized based on blood glucose monitoring, dietary intake, and physical activity. Hypoglycemia is the most common adverse effect and requires prompt recognition and management. Patients should be educated on proper injection techniques, storage conditions, and the importance of adherence to prescribed regimens. Xsulin R Eris1pen Injection should be used under medical supervision, with periodic monitoring of blood glucose and HbA1c levels to optimize therapeutic outcomes.